Medical University of South Carolina

Institutional Biosafety Committee Meeting Minutes

Meeting Date	Thursday, September 11, 2025
Meeting Time	12:01 PM –1:29 PM
Meeting Type	Teams Meeting
IBC Members Present	1. Caroline Westwater, Ph.D., (IBC Chair) 2. John Woodward, Ph.D. (IBC Vice Chair) 3. Christina Voelkel-Johnson, Ph.D., (BSO) 4. Lisa Steed, Ph.D., (IBC Member) 5. Eric Meissner, M.D., (IBC Member) 6. Carlene Brandon, MS. (Local Non-affiliated Member) 7. Anastasia Zimmerman, Ph.D. (Local Non-affiliated Member) 8. Aimee McRae-Clar, Pharm.D., BCPP (IBC Alternate Member; Office of Research Integrity Director)
Quorum	Number of Members Present (Voting): 8 Number of Members Not Present: 3 Late Arrival of Voting Members: n/a Early Departure of Voting Members:1
Other Individuals in Attendance	Michael Smith, Ph.D., (IBC Manager) Gloriane Schnabolk Ph.D., (IACUC & IBC Senior Administrator)
Call to Order	The IBC Chair called the meeting to order at 12:01 PM
Conflicts of Interests	The IBC Chair reminded all members present to identify any conflicts of interest before each registration is reviewed.
Review and Approval of Previous Meeting Minutes	July 10, 2025, August 14, 2025, September 11, 2025 IBC meeting minutes will be discussed.
Review of Prior Business	Meeting minutes format discussion SOP signature discussion NIH launched Initiative to Modernize and Strengthen Biosafety Oversight.
New IBC Registration and Amendments for Review (repeat for each registration)	

Protocol #	IBC-25-308
PI Name	Bergmann, Shayla
Study Title	A phase 1/2 study evaluating the safety and efficacy of a single dose of autologous [redacted] base edited hematopoietic stem cells to increase [redacted] production.
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae

	☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☒ Other Autologous [redacted] base edited hematopoietic stem cells
rDNA Category	III-C
Genetically modified microbes or vectors	N/A
Transgene expression	[redacted]
Highest BSL	BSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Meissner	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-306
PI Name	Mulholland, Patrick
Study Title	Mulholland Lab IBC
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D-4-b
Genetically modified microbes or vectors	Adeno-Associated virus

Transgene expression	GCaMP reporters, OxLight1, Kcnq3, Cre, DREADDS, hChR2 h134R, ChroME-ST, SwiChRca, EYFP, mCherry, mRuby, EGFP, SaCas9.		
Highest BSL	BSL2, ABSL-2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☒ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-302
PI Name	Sambamurti, Kumar
Study Title	PA-Alzheimer's Drug Development Program (ADDP)-U01-L-DOPA
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☒ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D-4-b
Genetically modified microbes or vectors	Escherichia coli Nissle 1917
Transgene expression	E. coli HpaBC operon
Highest BSL	BSL2, ABSL-2
Training	☒ Complete ☐ Pending

Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☒ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-318
PI Name	Mehrotra, Meenal
Study Title	Bone and dental cell engineering
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☒ Gene modified mouse cells ☒ Gene modified human cells ☐ Other
rDNA Category	III-D1a
Genetically modified microbes or vectors	Lentiviral vector
Transgene expression	D36, SphK1/2, Spns2, S1P receptors, Akt, mTOR, IL10, ferritin light/heavy chains, BMPR, GSK3B, YAP
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☒ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-293		
PI Name	Tew, Ken		
Study Title	Investigating glutathione pathways for cancer drug development		
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☒ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☒ Gene modified rodent cells ☒ Gene modified human cells ☐ Other		
rDNA Category	III-D1a,, III-D4b		
Genetically modified microbes or vectors	Pichia pastoris; Lentiviral vector		
Transgene expression	Luciferase, GSTP, MGST1, Srx, Grx, Trx, GRP78, GPX4, tyrosinase, ER-alpha, PDI, VDAC		
Highest BSL	BSL2, ABSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☒ Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Westwater
Votes			

For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-319		
PI Name	Mehrotra, Shikhar		
Study Title	T cell Immunotherapy		
Agent	☐ Plasmid DNA/mRNA ☒ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☒ Biological toxins ☒ Gene modified rodent cells ☒ Gene modified human cells ☐ Other		
rDNA Category	III-D1a, III-D4b		
Genetically modified microbes or vectors	Retro-and lentiviral vectors		
Transgene expression	LC3-GFP-RFP, fluorescent and luminescent reporters, T cell receptor genes and CAR genes. Pim kinases, sphingosine kinases, sestrin family genes, lipase family genes, and purinoreceptor family genes, ER stress response genes, glucose transport, RNA binding, the delta opioid receptor, endocannabinoid receptors, lipid transporters, NAD metabolism, antioxidants, organelle biogenesis, gap junction family, heat and pain sensors/receptors, cystathionine-b-synthetase and acetyl CoA carboxylase, Tbet, Gata, IRF4, Runx1, Eomes, and FoxP3, Cas9		
Highest BSL	BSL2, ABSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☒ Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Meeting Adjournment	The IBC Chair called for the meeting to be adjourned at 1:29 PM